MiMedx Q3 2026 Sales Drop Amid Regulatory Shifts
MiMedx reported a 45% drop in net sales due to Wound Care declines, but delivered surgical volume growth and returned to positive Adjusted EBITDA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed